128th MAINE LEGISLATURE

FIRST REGULAR SESSION-2017

Legislative Document **No. 606**

H.P. 422 House of Representatives, February 16, 2017

An Act To Ensure Access to All Prescription Drugs Containing Cannabidiol Approved by the Federal Food and Drug Administration

Reference to the Committee on Health and Human Services suggested and ordered printed.

ROBERT B. HUNT
Clerk

Presented by Representative AUSTIN of Gray.
Cosponsored by Representatives: FECTEAU of Biddeford, HANLEY of Pittston, KINNEY of Knox, PICKETT of Dixfield, STEARNS of Guilford, WARD of Dedham, WHITE of Washburn.

Be it enacted by the People of the State of Maine as follows:

Sec. 1. 22 MRSA §2430-C is enacted to read:

§2430-C. Federal approval of cannabidiol

1. Federal approval. A prescription medication containing cannabidiol that is approved pursuant to 21 United States Code, Section 360bb and 21 United States Code, Section 355 or under a federal interim final rule issued pursuant to 21 United States Code, Section 811(j) must be available in this State with similar control or decontrol within 30 days of publication in the Federal Register of the interim final rule or federal final rule.

2. Emergency. Control or decontrol under this section in conformance with federal law or rule may be altered by the Legislature or by emergency rule adopted by the department to address an immediate danger to public health, safety or welfare.

3. Scope. This section may not otherwise restrict or affect access to marijuana authorized under this chapter.

SUMMARY

This bill states that a prescription medication containing cannabidiol that is approved by federal law or rule must be available in this State within 30 days of approval or publication in the Federal Register.